Rifapentine 600 mg and INH 300 mg + Rifapentine 900 mg and INH 900 mg
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Tuberculosis
Conditions
Tuberculosis
Trial Timeline
Mar 24, 2022 → Jun 10, 2024
NCT ID
NCT04703075About Rifapentine 600 mg and INH 300 mg + Rifapentine 900 mg and INH 900 mg
Rifapentine 600 mg and INH 300 mg + Rifapentine 900 mg and INH 900 mg is a approved stage product being developed by Sanofi for Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04703075. Target conditions include Tuberculosis.
What happened to similar drugs?
2 of 4 similar drugs in Tuberculosis were approved
Approved (2) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04703075 | Approved | Completed |
Competing Products
20 competing products in Tuberculosis